Stonehearth Capital Management LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 35.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,825 shares of the company’s stock after acquiring an additional 1,010 shares during the quarter. Stonehearth Capital Management LLC’s holdings in Johnson & Johnson were worth $533,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Highwater Wealth Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at $215,000. Alta Capital Management LLC grew its holdings in Johnson & Johnson by 12.5% in the 4th quarter. Alta Capital Management LLC now owns 1,800 shares of the company’s stock valued at $232,000 after buying an additional 200 shares in the last quarter. Grassi Investment Management grew its holdings in Johnson & Johnson by 10.5% in the 4th quarter. Grassi Investment Management now owns 67,530 shares of the company’s stock valued at $8,715,000 after buying an additional 6,405 shares in the last quarter. Arlington Partners LLC grew its holdings in Johnson & Johnson by 3.0% in the 4th quarter. Arlington Partners LLC now owns 8,400 shares of the company’s stock valued at $1,084,000 after buying an additional 245 shares in the last quarter. Finally, Lynch & Associates IN grew its holdings in Johnson & Johnson by 1.7% in the 4th quarter. Lynch & Associates IN now owns 97,145 shares of the company’s stock valued at $12,537,000 after buying an additional 1,648 shares in the last quarter. 66.83% of the stock is currently owned by hedge funds and other institutional investors.
In other Johnson & Johnson news, Director Marillyn A. Hewson purchased 3,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The shares were acquired at an average price of $139.68 per share, with a total value of $419,040.00. Following the purchase, the director now directly owns 3,000 shares in the company, valued at approximately $419,040. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.23% of the company’s stock.
Shares of Johnson & Johnson stock opened at $129.78 on Thursday. Johnson & Johnson has a 52 week low of $121.00 and a 52 week high of $148.99. The company has a fifty day simple moving average of $138.09. The firm has a market cap of $342.08 billion, a price-to-earnings ratio of 15.87, a PEG ratio of 2.18 and a beta of 0.70. The company has a current ratio of 1.44, a quick ratio of 1.13 and a debt-to-equity ratio of 0.47.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.57% and a net margin of 20.08%. The business had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same quarter in the prior year, the company posted $2.10 EPS. The company’s quarterly revenue was down 1.3% on a year-over-year basis. On average, research analysts expect that Johnson & Johnson will post 8.6 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 2.93%. The ex-dividend date of this dividend is Monday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Net Margin – Understanding the Different Kinds of Profit
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.